Skip to main content

Table 2 Descriptive report of different treatment regimens’ effect on COVID-19 transplant patients' outcome

From: Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?

Drugs Length of stay; mean ± SEM* O2 therapy (%) Mortality (%)
Intensive care unit stay Hospital Mechanical ventilation used Mechanical ventilation not used Yes No
Hydroxychloroquine
No 16.22 ± 9.87 27.21 ± 15.32 11 (19) 155 (83) 8 (40) 158 (70)
Yes 20.98 ± 10.09 30.87 ± 15 48 (81) 31 (17) 12 (60) 67 (30)
Interferon
No 17.70 ± 15.44 26.59 ± 13.90 49 (83) 41 (48) 11 (55) 79 (35)
Yes 22.88 ± 16.79 31.11 ± 14.00 10 (17) 45 (52) 9 (45) 46 (20)
Lopinavir/Ritonavir
No 20.19 + 16.60 24.40 ± 14.00 15 (25) 40 (47) 1 (5) 54 (24)
Yes 27.60 ± 15.43 34.30 ± 16.99 44 (75) 46 (53) 19 (95) 71 (32)
Remdesivir
No 24.31 ± 12.41 34.45 ± 13.76 46 (78) 97 (52) 10 (50) 133 (59)
Yes 18.91 ± 10.00 27.00 ± 11.65 13 (22) 89 (48) 10 (50) 92 (41)
Tocilizumab
No 23.30 ± 13.13 31.11 ± 12.00 49 (82) 136 (74) 13 (65) 172 (76)
Yes 18.83 ± 10.90 28.00 ± 14.10 11 (18) 49 (26) 7 (35) 53 (24)
Dexamethasone or High dose methylprednisolone
No 24.33 ± 13.00 33.30 ± 13.00 45 (76) 64 (34) 9 (45) 100 (44)
Yes 19.77 ± 12.00 29.70 ± 11.10 14 (24) 122 (66) 11 (55) 125 (56)
  1. *Standard error of the mean